Contrary to seeking fully de-risked assets, pharmaceutical companies often prefer acquiring companies with some remaining clinical risk. This strategy allows them to leverage unique insights on early data to acquire assets at a better valuation, creating an opportunity for outsized returns before the value is obvious to others.

It's a fool's errand to predict specific trial results. A robust quantitative approach to biotech focuses on underlying drivers and base rates. It positions a portfolio so the random, unpredictable nature of trial events plays out favorably over time, guided by factors like valuation and specialist ownership.

The strong biotech market performance in 2025 was not a case of a rising tide lifting all boats. Outperformance was concentrated in companies with strong fundamentals and backing from specialist investors, indicating a healthy, discerning market that rewards quality over speculation.

In biotech investing, the collective wisdom of specialists is more valuable than any single expert's contrarian bet. Stocks owned by multiple specialists perform better, suggesting that an individual specialist's unique, high-alpha idea is more likely to be wrong than right.

The life sciences investor base is highly technical, demanding concrete data and a clear path to profitability. This rigor acts as a natural barrier to the kind of narrative-driven, AI-fueled hype seen in other sectors, delaying froth until fundamental catalysts are proven.

The fundamental purpose of any biotech company is to leverage a novel technology or insight that increases the probability of clinical trial success. This reframes the mission away from just "cool science" to having a core thesis for beating the industry's dismal odds of getting a drug to market.

Abivax's drug was dismissed by many investors because its mechanism of action was unclear, a common red flag. However, the available clinical data was strong enough to suggest efficacy, meaning the "how" it worked was less important than the evidence "that" it worked for generating alpha.

Market dynamics, like investor fixation on AI or predatory short-selling, pose a greater risk to biotech firms than clinical trial results. A company can have a breakthrough drug but still fail if its stock—its funding currency—is ignored or attacked by Wall Street.

A common mistake in biotech investing is relying too heavily on a company's own data and presentations. To gain a true edge, investors should spend more time diligencing competitor drugs and the broader market landscape, as companies rarely provide an unbiased view of their competition.